Katsuyoshi Matsuoka1, Toshimitsu Fujii2, Ryuichi Okamoto2, Akihiro Yamada1, Reiko Kunisaki3, Minoru Matsuura4, Kenji Watanabe5, Hisashi Shiga6, Noritaka Takatsu7, Shigeki Bamba8, Yohei Mikami9, Takayuki Yamamoto10, Takahiro Shimoyama10, Satoshi Motoya11, Takehiro Torisu12, Taku Kobayashi13, Naoki Ohmiya14, Masayuki Saruta15, Koichiro Matsuda16, Takayuki Matsumoto17, Hiroshi Nakase18, Atsuo Maemoto19, Shinichiro Shinzaki5,20, Yoko Murata21, Shinichi Yoshigoe21, Ayako Sasaki21, Tsutomu Yajima22, Tadakazu Hisamatsu23. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Chiba, Japan. 2. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan. 3. Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Minami-ku, Yokohama, Kanagawa, Japan. 4. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan. 5. Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan. 6. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. 7. Department of Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. 8. Division of Digestive Endoscopy, Shiga University of Medical Science, Otsu, Shiga, Japan. 9. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjiku-ku, Tokyo, Japan. 10. Department of Surgery and Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, Yokkaichi, Mie, Japan. 11. IBD Center, Hokkaido Preventive Welfare Federation of Agricultural Cooperative, Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan. 12. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan. 13. Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan. 14. Department of Advanced Endoscopy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. 15. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. 16. Department of Gastroenterology, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan. 17. Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Iwate, Japan. 18. Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan. 19. IBD Center, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan. 20. Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. 21. Medical Affairs Division, Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo, Japan. 22. Statistics & Decision Sciences, Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo, Japan. 23. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan. thisamatsu@ks.kyorin-u.ac.jp.
Abstract
BACKGROUND: The Inception Cohort Registry Study of Patients with Crohn's Disease aimed to clarify clinical characteristics and disease course of newly diagnosed Crohn's disease patients in Japan throughout a 4-year period. Results from an interim analysis of the largest nation-wide registry study that covers approximately 1% of Crohn's disease patient population in Japan are reported. METHODS: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn's disease after June 2016 (age ≥ 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020. Patient demographics, diagnostic procedures and categories, disease location and lesion behavior (Montreal classification) at the time of diagnosis were recorded. RESULTS: Of 673 patients enrolled, 672 (99.9%) were analyzed (458: men, 214: women), male-to-female ratio: 2.1, median age at diagnosis 25 (range 13-86) years; peak age of disease diagnosis: 20-24 years. Most common disease location was L3 (ileocolonic; 60.1%). Non-stricturing, non-penetrating (B1) disease was most common behavior (62.8%); 48.9% reported perianal lesions. Notably, age-wise analysis revealed disease phenotypes varied between patients aged < 40 and ≥ 40 years in terms of male-to-female ratio (2.5/1.3)/disease location (L3: 66.3%/37.0%)/disease behavior (B1: 66.4%/50.0%)/perianal lesion: (55.7%/20.5%) at Crohn's disease diagnosis, respectively. CONCLUSIONS: Interim analysis of this nation-wide Inception Cohort Registry Study of Patients with Crohn's Disease revealed the demographics and disease characteristics of newly diagnosed Crohn's disease patients in Japan and demonstrated that disease phenotype varied between patients aged < 40 and ≥ 40 years, serving as important information for management of individual patients.
BACKGROUND: The Inception Cohort Registry Study of Patients with Crohn's Disease aimed to clarify clinical characteristics and disease course of newly diagnosed Crohn's disease patients in Japan throughout a 4-year period. Results from an interim analysis of the largest nation-wide registry study that covers approximately 1% of Crohn's disease patient population in Japan are reported. METHODS: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn's disease after June 2016 (age ≥ 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020. Patient demographics, diagnostic procedures and categories, disease location and lesion behavior (Montreal classification) at the time of diagnosis were recorded. RESULTS: Of 673 patients enrolled, 672 (99.9%) were analyzed (458: men, 214: women), male-to-female ratio: 2.1, median age at diagnosis 25 (range 13-86) years; peak age of disease diagnosis: 20-24 years. Most common disease location was L3 (ileocolonic; 60.1%). Non-stricturing, non-penetrating (B1) disease was most common behavior (62.8%); 48.9% reported perianal lesions. Notably, age-wise analysis revealed disease phenotypes varied between patients aged < 40 and ≥ 40 years in terms of male-to-female ratio (2.5/1.3)/disease location (L3: 66.3%/37.0%)/disease behavior (B1: 66.4%/50.0%)/perianal lesion: (55.7%/20.5%) at Crohn's disease diagnosis, respectively. CONCLUSIONS: Interim analysis of this nation-wide Inception Cohort Registry Study of Patients with Crohn's Disease revealed the demographics and disease characteristics of newly diagnosed Crohn's disease patients in Japan and demonstrated that disease phenotype varied between patients aged < 40 and ≥ 40 years, serving as important information for management of individual patients.
Authors: J Burisch; N Pedersen; S Cukovic-Cavka; N Turk; I Kaimakliotis; D Duricova; M Bortlik; O Shonová; I Vind; S Avnstrøm; N Thorsgaard; S Krabbe; V Andersen; J F Dahlerup; J Kjeldsen; R Salupere; J Olsen; K R Nielsen; P Manninen; P Collin; K H Katsanos; E V Tsianos; K Ladefoged; L Lakatos; G Ragnarsson; E Björnsson; Y Bailey; C O'Morain; D Schwartz; S Odes; M Giannotta; G Girardin; G Kiudelis; L Kupcinskas; S Turcan; L Barros; F Magro; D Lazar; A Goldis; I Nikulina; E Belousova; D Martinez-Ares; V Hernandez; S Almer; Y Zhulina; J Halfvarson; N Arebi; H H Tsai; S Sebastian; P L Lakatos; E Langholz; P Munkholm Journal: J Crohns Colitis Date: 2013-12-07 Impact factor: 9.071
Authors: F L Wolters; M G Russel; J Sijbrandij; T Ambergen; S Odes; L Riis; E Langholz; P Politi; A Qasim; I Koutroubakis; E Tsianos; S Vermeire; J Freitas; G van Zeijl; O Hoie; T Bernklev; M Beltrami; D Rodriguez; R W Stockbrügger; B Moum Journal: Gut Date: 2005-12-16 Impact factor: 23.059
Authors: N Morita; S Toki; T Hirohashi; T Minoda; K Ogawa; S Kono; A Tamakoshi; Y Ohno; T Sawada; T Muto Journal: J Gastroenterol Date: 1995-11 Impact factor: 7.527
Authors: J Burisch; N Pedersen; S Čuković-Čavka; M Brinar; I Kaimakliotis; D Duricova; O Shonová; I Vind; S Avnstrøm; N Thorsgaard; V Andersen; S Krabbe; J F Dahlerup; R Salupere; K R Nielsen; J Olsen; P Manninen; P Collin; E V Tsianos; K H Katsanos; K Ladefoged; L Lakatos; E Björnsson; G Ragnarsson; Y Bailey; S Odes; D Schwartz; M Martinato; G Lupinacci; M Milla; A De Padova; R D'Incà; M Beltrami; L Kupcinskas; G Kiudelis; S Turcan; O Tighineanu; I Mihu; F Magro; L F Barros; A Goldis; D Lazar; E Belousova; I Nikulina; V Hernandez; D Martinez-Ares; S Almer; Y Zhulina; J Halfvarson; N Arebi; S Sebastian; P L Lakatos; E Langholz; P Munkholm Journal: Gut Date: 2013-04-20 Impact factor: 23.059